Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07461831) titled 'CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma' on March 5.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Beijing Tongren Hospital

Condition: Large B-Cell Lymphoma (LBCL)

Intervention: Drug: CD19/CD22 bispecific CAR-T cells

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: February 1, 2022

Target Sample Size: 100

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07461831

P...